8-K: Precigen Advances PRGN-2012 Towards BLA Submission and Reports Q3 2024 Results

Precigen reports progress on its lead candidate PRGN-2012, including alignment with the FDA for a BLA submission, while also detailing its third quarter 2024 financial results.

Summary

• Precigen announced its third quarter 2024 financial results and provided updates on its clinical programs.
• The company is preparing for a Biologics License Application (BLA) submission for PRGN-2012 in the fourth quarter of 2024, having completed a pre-BLA meeting with the FDA.
• A commercial and manufacturing readiness campaign is underway for PRGN-2012, anticipating a potential launch in 2025.
• A confirmatory clinical trial for PRGN-2012 has been initiated, as per FDA guidance.
• Preclinical data for PRGN-3008, a next-generation UltraCAR-T therapy, was presented at SITC 2024, showing potential as a best-in-class CD19-targeting treatment.
• The company completed a public offering in August 2024, raising approximately $30.9 million after expenses.
• A strategic reprioritization of the portfolio and a workforce reduction of over 20% were implemented to focus on PRGN-2012.
• Third quarter 2024 net loss was $24.0 million, or $(0.09) per share, compared to a net loss of $19.8 million, or $(0.08) per share, in the same period of 2023.
• Total revenues decreased by $0.4 million, or 31%, compared to the third quarter of 2023, primarily due to reduced product and service revenues at Exemplar.
• For the first nine months of 2024, the net loss was $106.5 million, or $(0.41) per share, compared to a net loss of $62.8 million, or $(0.26) per share, in the same period of 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. There is positive progress on the clinical front with PRGN-2012 and PRGN-3008, but the financial results show increased losses and decreased revenue. The strategic reprioritization and workforce reduction are necessary but also reflect challenges. The sentiment is cautiously optimistic.

Positives

• The company has achieved full alignment with the FDA on the BLA content for PRGN-2012.
• PRGN-2012 demonstrated strong efficacy in clinical trials, with a high percentage of patients achieving complete responses and reduced surgical interventions.
• PRGN-2012 was well-tolerated with no dose-limiting toxicities or treatment-related adverse events greater than Grade 2.
• Preclinical data for PRGN-3008 suggests it could be a best-in-class CD19-targeting treatment.
• The company successfully raised $30.9 million through a public offering.
• The strategic reprioritization is expected to streamline operations and focus resources on the most promising programs.

Negatives

• The company reported a net loss of $24.0 million for the third quarter of 2024, which is higher than the $19.8 million loss in the same period of 2023.
• Total revenues decreased by 31% in the third quarter of 2024 compared to the same period in 2023.
• The company incurred $34.5 million of impairment charges related to goodwill and long-lived assets due to the suspension of ActoBio's operations.
• The company has paused enrollment in the cervical cancer Phase 2 clinical trial at non-NCI sites.

Risks

• The company's future success is dependent on the successful development and commercialization of PRGN-2012.
• There are risks associated with the regulatory approval process for PRGN-2012.
• The company may face challenges in manufacturing and commercializing PRGN-2012.
• The company's financial performance is subject to fluctuations in revenue and expenses.
• The company is dependent on securing additional financing to support its operations and development programs.
• The company faces competition from other companies developing similar therapies.

Future Outlook

The company is focused on the potential commercialization of PRGN-2012 and is exploring strategic partnerships and other financing options. They plan to update investors on their progress in the coming months.

Management Comments

• Helen Sabzevari, PhD, President and CEO of Precigen, stated that the strategic reprioritization has enabled the company to focus on advancing PRGN-2012 as rapidly as possible and that they are excited about the imminent BLA submission.
• Harry Thomasian Jr., CFO of Precigen, mentioned that the company is making good progress on potential financing options and will update investors in the coming months.

Industry Context

This announcement reflects the broader trend in the biopharmaceutical industry of focusing on promising lead candidates and streamlining operations to achieve commercial success. The development of novel gene and cell therapies, such as PRGN-2012 and PRGN-3008, is a key area of innovation in the treatment of cancer and other diseases.

Comparison to Industry Standards

• The 51% complete response rate for PRGN-2012 in RRP patients is a significant achievement, potentially exceeding the efficacy of existing treatments for this rare disease. Companies such as Genentech and Regeneron have also developed therapies for rare diseases, but the specific efficacy and safety profiles vary.
• The development of next-generation CAR-T therapies like PRGN-3008, with features such as enhanced persistence and built-in PD-1 blockade, is in line with the industry's push to improve upon first-generation CAR-T treatments. Companies like Novartis and Gilead have established CAR-T therapies, but Precigen's approach with non-viral transposon technology and overnight manufacturing could offer advantages.
• The financial results show a net loss, which is common for clinical-stage biopharmaceutical companies. However, the increase in net loss compared to the previous year highlights the need for effective cost management and successful commercialization of their products. Companies like bluebird bio and CRISPR Therapeutics have also faced financial challenges while developing their gene therapies.

Stakeholder Impact

• Shareholders may be impacted by the increased net loss and the strategic reprioritization, but also by the potential for successful commercialization of PRGN-2012.
• Employees were impacted by the workforce reduction of over 20%.
• Patients with RRP may benefit from the potential approval and launch of PRGN-2012.
• The company's suppliers and partners may be impacted by the changes in the company's operations and focus.

Next Steps

• The company plans to submit a rolling BLA for PRGN-2012 in the fourth quarter of 2024.
• They will continue the commercial and manufacturing readiness campaign for PRGN-2012.
• The company will prepare for an end of Phase 1b meeting with the FDA for PRGN-3006 in early 2025.
• They will continue to explore strategic partnerships and other financing options.
• The company will update investors on their progress in the coming months.

Key Dates

Keywords

PRGN-2012, UltraCAR-T, gene therapy, biopharmaceutical, BLA, FDA, RRP, oncology, autoimmune, clinical trial, financial results, CD19, AdenoVerse